Dimension Board Determines that Ultragenyx’s Unsolicited Proposal to Acquire Dimension for $6.00 Per Share Constitutes a “Superior Proposal”
02 oct. 2017 08h00 HE
|
Dimension Therapeutics
REGENXBIO Waives Matching Rights CAMBRIDGE, Mass., Oct. 02, 2017 (GLOBE NEWSWIRE) -- Dimension Therapeutics, Inc. (“Dimension”) (NASDAQ:DMTX) announced today that the Dimension Board of Directors...
Dimension Board of Directors Determines Proposal from Ultragenyx Pharmaceutical Inc. Could Reasonably Be Expected to Lead to a “Superior Proposal”
19 sept. 2017 08h00 HE
|
Dimension Therapeutics
CAMBRIDGE, Mass., Sept. 19, 2017 (GLOBE NEWSWIRE) -- Dimension Therapeutics, Inc. (Nasdaq:DMTX), a leader in discovering and developing new therapeutic products for people living with devastating...
Dimension Confirms Receipt of Unsolicited Proposal from Ultragenyx
18 sept. 2017 15h10 HE
|
Dimension Therapeutics
CAMBRIDGE, Mass., Sept. 18, 2017 (GLOBE NEWSWIRE) -- Dimension Therapeutics, Inc. (Nasdaq:DMTX) (“Dimension”), a leader in discovering and developing new therapeutic products for people living with...
Dimension Therapeutics Commences Patient Dosing in Global, Multi-Center Phase 1/2 Clinical Trial of DTX301 in Ornithine Transcarbamylase (OTC) Deficiency
31 août 2017 08h00 HE
|
Dimension Therapeutics
Twelve trial sites recruiting patients with OTC deficiency in the United States, United Kingdom, Spain, and Canada Initial data from the company’s Phase 1/2 study anticipated by late 2017 CAMBRIDGE,...
Dimension Therapeutics Reports Second Quarter 2017 Financial Results and Provides Corporate Update
08 août 2017 08h00 HE
|
Dimension Therapeutics
Initial data from Phase 1/2 clinical trial of DTX301, Dimension’s lead AAV8 vector product candidate for OTC deficiency, expected year end 2017 IND filings for GSDIa and Hemophilia A programs...
Dimension Therapeutics Announces Management Change
24 juil. 2017 08h00 HE
|
Dimension Therapeutics
CAMBRIDGE, Mass., July 24, 2017 (GLOBE NEWSWIRE) -- Dimension Therapeutics, Inc. (NASDAQ:DMTX), a biopharmaceutical company advancing novel, adeno-associated virus (AAV) gene therapies targeting the...
Dimension Therapeutics Completes Strategic Review and Updates Corporate Priorities
27 juin 2017 08h00 HE
|
Dimension Therapeutics
Initial data from Phase 1/2 clinical trial of DTX301, Dimension’s lead AAV8 vector product candidate for OTC deficiency, expected year end 2017 IND filings for GSDIa and Hemophilia A expected in...
Dimension Therapeutics Reports First Quarter 2017 Financial Results and Provides Corporate Update
10 mai 2017 08h00 HE
|
Dimension Therapeutics
Discontinues Clinical Development of DTX101, an AAVrh10 Factor IX Gene Therapy Product Candidate for Moderate/Severe-to-Severe Hemophilia B Initial data from Phase 1/2 clinical trial of DTX301,...
Dimension Therapeutics Announces Presentations at the Upcoming American Society for Gene and Cell Therapy (ASGCT) Annual Meeting
24 avr. 2017 12h05 HE
|
Dimension Therapeutics
CAMBRIDGE, Mass., April 24, 2017 (GLOBE NEWSWIRE) -- Dimension Therapeutics, Inc. (NASDAQ:DMTX), a biopharmaceutical company advancing novel, adeno-associated virus (AAV) gene therapies targeting...
Dimension Therapeutics Announces Full Year 2016 Financial Results and Recent Updates Across Rare and Metabolic Disease Portfolio and in HeLa Manufacturing
09 mars 2017 07h30 HE
|
Dimension Therapeutics
In December, initiated Phase 1/2 clinical trial of DTX301, Dimension’s lead IMD product candidate for OTC Deficiency; Initial data expected 2H 2017 Updates interim results from Phase 1/2 clinical...